Prognostic Influence of Residual Tumor-Infiltrating Lymphocyte Subtype After Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer

ObjectiveThis study aimed to examine the prevalence and prognostic role of tumor microenvironment (TME) in triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy (NACT) through immunohistochemical characterization.MethodsThe internal database of the Brazilian National Cancer Institute f...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jesse Lopes da Silva, Lucas Zanetti de Albuquerque, Fabiana Resende Rodrigues, Guilherme Gomes de Mesquita, Priscila Valverde Fernandes, Luiz Claudio Santos Thuler, Andreia Cristina de Melo
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	triple-negative breast cancer tumor-infiltrating lymphocyte tumor microenvironment neoadjuvant chemotherapy biomarkers Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/be0aba341d474568a03c2e86268d7509
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:be0aba341d474568a03c2e86268d7509
record_format	dspace
spelling	oai:doaj.org-article:be0aba341d474568a03c2e86268d75092021-11-09T06:44:10ZPrognostic Influence of Residual Tumor-Infiltrating Lymphocyte Subtype After Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer2234-943X10.3389/fonc.2021.636716https://doaj.org/article/be0aba341d474568a03c2e86268d75092021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.636716/fullhttps://doaj.org/toc/2234-943XObjectiveThis study aimed to examine the prevalence and prognostic role of tumor microenvironment (TME) in triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy (NACT) through immunohistochemical characterization.MethodsThe internal database of the Brazilian National Cancer Institute for women diagnosed with TNBC who underwent NACT and thereafter curative surgery between January 2010 and December 2014 was queried out. Core biopsy specimens and tissue microarrays containing surgical samples of TNBC from 171 and 134 women, respectively, were assessed by immunohistochemistry for CD3, CD4, CD8, CD14, CD56, CD68, CD117, FOXP3, PD-1, PD-L1, and PD-L2. Immune cell profiles were analyzed and correlated with response and survival.ResultsMean age was 50.5 years, and most cases were clinical stage III [143 cases (83.6%)]. According to the multivariate analysis, only Ki67 and clinical stage significantly influenced the pattern of response to systemic treatment (p = 0.019 and p = 0.033, respectively). None of the pre-NACT IHC markers showed a significant association with event-free survival (EFS) or overall survival (OS). As for post-NACT markers, patients with high CD14 had significantly shorter EFS (p = 0.015), while patients with high CD3 (p = 0.025), CD4 (p = 0.025), CD8 (p = 0.030), CD14 (p = 0.015), FOXP3 (p = 0.005), high CD4/FOXP3 (p = 0.034), and CD8/FOXP3 (p = 0.008) showed longer EFS. Only high post-NACT CD4 showed significantly influenced OS (p = 0.038).ConclusionThe present study demonstrated that the post-NACT TIL subtype can be a determining factor in the prognosis of patients with TNBC.Jesse Lopes da SilvaLucas Zanetti de AlbuquerqueFabiana Resende RodriguesGuilherme Gomes de MesquitaGuilherme Gomes de MesquitaPriscila Valverde FernandesLuiz Claudio Santos ThulerAndreia Cristina de MeloFrontiers Media S.A.articletriple-negative breast cancertumor-infiltrating lymphocytetumor microenvironmentneoadjuvant chemotherapybiomarkersNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	triple-negative breast cancer tumor-infiltrating lymphocyte tumor microenvironment neoadjuvant chemotherapy biomarkers Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	triple-negative breast cancer tumor-infiltrating lymphocyte tumor microenvironment neoadjuvant chemotherapy biomarkers Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Jesse Lopes da Silva Lucas Zanetti de Albuquerque Fabiana Resende Rodrigues Guilherme Gomes de Mesquita Guilherme Gomes de Mesquita Priscila Valverde Fernandes Luiz Claudio Santos Thuler Andreia Cristina de Melo Prognostic Influence of Residual Tumor-Infiltrating Lymphocyte Subtype After Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
description	ObjectiveThis study aimed to examine the prevalence and prognostic role of tumor microenvironment (TME) in triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy (NACT) through immunohistochemical characterization.MethodsThe internal database of the Brazilian National Cancer Institute for women diagnosed with TNBC who underwent NACT and thereafter curative surgery between January 2010 and December 2014 was queried out. Core biopsy specimens and tissue microarrays containing surgical samples of TNBC from 171 and 134 women, respectively, were assessed by immunohistochemistry for CD3, CD4, CD8, CD14, CD56, CD68, CD117, FOXP3, PD-1, PD-L1, and PD-L2. Immune cell profiles were analyzed and correlated with response and survival.ResultsMean age was 50.5 years, and most cases were clinical stage III [143 cases (83.6%)]. According to the multivariate analysis, only Ki67 and clinical stage significantly influenced the pattern of response to systemic treatment (p = 0.019 and p = 0.033, respectively). None of the pre-NACT IHC markers showed a significant association with event-free survival (EFS) or overall survival (OS). As for post-NACT markers, patients with high CD14 had significantly shorter EFS (p = 0.015), while patients with high CD3 (p = 0.025), CD4 (p = 0.025), CD8 (p = 0.030), CD14 (p = 0.015), FOXP3 (p = 0.005), high CD4/FOXP3 (p = 0.034), and CD8/FOXP3 (p = 0.008) showed longer EFS. Only high post-NACT CD4 showed significantly influenced OS (p = 0.038).ConclusionThe present study demonstrated that the post-NACT TIL subtype can be a determining factor in the prognosis of patients with TNBC.
format	article
author	Jesse Lopes da Silva Lucas Zanetti de Albuquerque Fabiana Resende Rodrigues Guilherme Gomes de Mesquita Guilherme Gomes de Mesquita Priscila Valverde Fernandes Luiz Claudio Santos Thuler Andreia Cristina de Melo
author_facet	Jesse Lopes da Silva Lucas Zanetti de Albuquerque Fabiana Resende Rodrigues Guilherme Gomes de Mesquita Guilherme Gomes de Mesquita Priscila Valverde Fernandes Luiz Claudio Santos Thuler Andreia Cristina de Melo
author_sort	Jesse Lopes da Silva
title	Prognostic Influence of Residual Tumor-Infiltrating Lymphocyte Subtype After Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
title_short	Prognostic Influence of Residual Tumor-Infiltrating Lymphocyte Subtype After Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
title_full	Prognostic Influence of Residual Tumor-Infiltrating Lymphocyte Subtype After Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
title_fullStr	Prognostic Influence of Residual Tumor-Infiltrating Lymphocyte Subtype After Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
title_full_unstemmed	Prognostic Influence of Residual Tumor-Infiltrating Lymphocyte Subtype After Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
title_sort	prognostic influence of residual tumor-infiltrating lymphocyte subtype after neoadjuvant chemotherapy in triple-negative breast cancer
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/be0aba341d474568a03c2e86268d7509
work_keys_str_mv	AT jesselopesdasilva prognosticinfluenceofresidualtumorinfiltratinglymphocytesubtypeafterneoadjuvantchemotherapyintriplenegativebreastcancer AT lucaszanettidealbuquerque prognosticinfluenceofresidualtumorinfiltratinglymphocytesubtypeafterneoadjuvantchemotherapyintriplenegativebreastcancer AT fabianaresenderodrigues prognosticinfluenceofresidualtumorinfiltratinglymphocytesubtypeafterneoadjuvantchemotherapyintriplenegativebreastcancer AT guilhermegomesdemesquita prognosticinfluenceofresidualtumorinfiltratinglymphocytesubtypeafterneoadjuvantchemotherapyintriplenegativebreastcancer AT guilhermegomesdemesquita prognosticinfluenceofresidualtumorinfiltratinglymphocytesubtypeafterneoadjuvantchemotherapyintriplenegativebreastcancer AT priscilavalverdefernandes prognosticinfluenceofresidualtumorinfiltratinglymphocytesubtypeafterneoadjuvantchemotherapyintriplenegativebreastcancer AT luizclaudiosantosthuler prognosticinfluenceofresidualtumorinfiltratinglymphocytesubtypeafterneoadjuvantchemotherapyintriplenegativebreastcancer AT andreiacristinademelo prognosticinfluenceofresidualtumorinfiltratinglymphocytesubtypeafterneoadjuvantchemotherapyintriplenegativebreastcancer
_version_	1718441240846925824

Prognostic Influence of Residual Tumor-Infiltrating Lymphocyte Subtype After Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer

Ejemplares similares